Physician profile
Robert J Bross
NPI 1538142054
$1,919.58
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $406 · 2021: $173 · 2022: $85.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $250.45 | 2019-2020 | |
| Lilly USA, LLC | $238.18 | 2019-2020 | |
| Novo Nordisk INC | $202.22 | 2019-2022 | |
| Abbvie INC. | $171.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $126.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $113.28 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $86.76 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $84.49 | 2019-2020 | |
| Astellas Pharma US INC | $72.64 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.70 | 2019 | |
| Amarin Pharma, INC. | $60.33 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $58.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $56.91 | 2019 | |
| Eisai INC. | $41.56 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $39.73 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $28.65 | 2019 | |
| Glaxosmithkline, LLC. | $27.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.55 | 2019 | |
| Genentech USA, INC. | $25.84 | 2019-2020 | |
| Seqirus USA INC | $15.86 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.79 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.74 | 2020 | |
| Sanofi Pasteur INC. | $14.15 | 2019 | |
| Amgen INC. | $13.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.22 | 2019 | |
| Circassia INC. | $13.14 | 2019 | |
| Bausch Health US, LLC | $12.48 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.69 | 2021 | |
| Boston Scientific Corporation | $11.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.